Acurx Pharmaceuticals (NASDAQ:ACXP) Announces Earnings Results, Beats Estimates By $0.03 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP) released its quarterly earnings data on Monday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03, Zacks reports.

Acurx Pharmaceuticals Stock Performance

Shares of ACXP stock traded down $0.01 during midday trading on Tuesday, hitting $0.39. 151,085 shares of the company were exchanged, compared to its average volume of 160,695. The firm has a market capitalization of $8.69 million, a P/E ratio of -0.36 and a beta of -1.37. Acurx Pharmaceuticals has a 52 week low of $0.30 and a 52 week high of $3.33. The firm’s 50 day moving average price is $0.40 and its two-hundred day moving average price is $0.81.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Acurx Pharmaceuticals in a research note on Wednesday, March 19th.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.